Cargando…

Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank

BACKGROUND: Mildly elevated bilirubin, a by-product of hemoglobin breakdown, might mitigate cardiometabolic risk factors including adiposity, dyslipidemia, and high blood pressure (BP). We investigated the cross-sectional relationship between (total) bilirubin and baseline cardiometabolic risk facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyed Khoei, Nazlisadat, Wagner, Karl-Heinz, Sedlmeier, Anja M., Gunter, Marc J., Murphy, Neil, Freisling, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017025/
https://www.ncbi.nlm.nih.gov/pubmed/35436955
http://dx.doi.org/10.1186/s12933-022-01484-x
_version_ 1784688685934968832
author Seyed Khoei, Nazlisadat
Wagner, Karl-Heinz
Sedlmeier, Anja M.
Gunter, Marc J.
Murphy, Neil
Freisling, Heinz
author_facet Seyed Khoei, Nazlisadat
Wagner, Karl-Heinz
Sedlmeier, Anja M.
Gunter, Marc J.
Murphy, Neil
Freisling, Heinz
author_sort Seyed Khoei, Nazlisadat
collection PubMed
description BACKGROUND: Mildly elevated bilirubin, a by-product of hemoglobin breakdown, might mitigate cardiometabolic risk factors including adiposity, dyslipidemia, and high blood pressure (BP). We investigated the cross-sectional relationship between (total) bilirubin and baseline cardiometabolic risk factors in 467,519 UK Biobank study participants. METHODS: We used multivariable-adjusted linear regression to estimate associations between bilirubin levels and risk factors of cardiometabolic diseases including body mass index (BMI), waist and hip circumferences (WC, HC), waist-to-hip ratio (WHR), fat mass (FM), and trunk FM, and the blood lipids: apolipoprotein A-I (apoA-I), apolipoprotein B (apoB), apoB/apoA-I, lipoprotein (a), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), LDL/HDL, TC/HDL, triglycerides (TG). Log-transformed bilirubin was modelled with restricted cubic splines and predicted mean values with 99% confidence intervals (CI) for each risk marker were estimated, separately. Second, we applied principal component analysis (PCA) for dimension reduction to in turn six anthropometric traits (height, weight, BMI, WC, HC, and WHR) and all above lipids. Last, we estimated associations (99%CI) between bilirubin and three components of the metabolic syndrome, i.e. WC, TG, and BP using logistic regression. RESULTS: After multivariable adjustments, higher levels of bilirubin were inversely associated with indicators of general adiposity (BMI and FM) and of body fat distribution (WC, HC, WHR, and trunk FM) in both men and women. For example, women with mildly elevated bilirubin (95(th) percentile equal to 15.0 µmol/L), compared to women with low bilirubin (5(th) percentile equal to 4.5 µmol/L), had on average a 2.0 kg/m(2) (99% CI 1.9–2.1) lower BMI. Inverse associations were also observed with dyslipidemia among men and women. For example, mildly elevated bilirubin among men (95(th) percentile equal to 19.4 µmol/L) compared to low levels of bilirubin (5(th) percentile equal to 5.5 µmol/L) were associated with approx. 0.55 mmol/L (99% CI 0.53–0.56) lower TG levels, with similar inverse associations among women. Multiple-trait analyses using PCA confirmed single-trait analyses. Men and women with mildly elevated bilirubin levels ≥ 17.1 µmol/L, compared to low-normal bilirubin < 10 µmol/L had 13% (99% CI 8%–18%) and 11% (99% CI 4%–17%) lower odds of exceeding systolic BP levels of ≥ 130 mm Hg, respectively. CONCLUSIONS: Higher levels of bilirubin were inversely associated with cardiometabolic risk factors including adiposity, dyslipidemia, and hypertension. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01484-x.
format Online
Article
Text
id pubmed-9017025
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90170252022-04-20 Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank Seyed Khoei, Nazlisadat Wagner, Karl-Heinz Sedlmeier, Anja M. Gunter, Marc J. Murphy, Neil Freisling, Heinz Cardiovasc Diabetol Research BACKGROUND: Mildly elevated bilirubin, a by-product of hemoglobin breakdown, might mitigate cardiometabolic risk factors including adiposity, dyslipidemia, and high blood pressure (BP). We investigated the cross-sectional relationship between (total) bilirubin and baseline cardiometabolic risk factors in 467,519 UK Biobank study participants. METHODS: We used multivariable-adjusted linear regression to estimate associations between bilirubin levels and risk factors of cardiometabolic diseases including body mass index (BMI), waist and hip circumferences (WC, HC), waist-to-hip ratio (WHR), fat mass (FM), and trunk FM, and the blood lipids: apolipoprotein A-I (apoA-I), apolipoprotein B (apoB), apoB/apoA-I, lipoprotein (a), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), LDL/HDL, TC/HDL, triglycerides (TG). Log-transformed bilirubin was modelled with restricted cubic splines and predicted mean values with 99% confidence intervals (CI) for each risk marker were estimated, separately. Second, we applied principal component analysis (PCA) for dimension reduction to in turn six anthropometric traits (height, weight, BMI, WC, HC, and WHR) and all above lipids. Last, we estimated associations (99%CI) between bilirubin and three components of the metabolic syndrome, i.e. WC, TG, and BP using logistic regression. RESULTS: After multivariable adjustments, higher levels of bilirubin were inversely associated with indicators of general adiposity (BMI and FM) and of body fat distribution (WC, HC, WHR, and trunk FM) in both men and women. For example, women with mildly elevated bilirubin (95(th) percentile equal to 15.0 µmol/L), compared to women with low bilirubin (5(th) percentile equal to 4.5 µmol/L), had on average a 2.0 kg/m(2) (99% CI 1.9–2.1) lower BMI. Inverse associations were also observed with dyslipidemia among men and women. For example, mildly elevated bilirubin among men (95(th) percentile equal to 19.4 µmol/L) compared to low levels of bilirubin (5(th) percentile equal to 5.5 µmol/L) were associated with approx. 0.55 mmol/L (99% CI 0.53–0.56) lower TG levels, with similar inverse associations among women. Multiple-trait analyses using PCA confirmed single-trait analyses. Men and women with mildly elevated bilirubin levels ≥ 17.1 µmol/L, compared to low-normal bilirubin < 10 µmol/L had 13% (99% CI 8%–18%) and 11% (99% CI 4%–17%) lower odds of exceeding systolic BP levels of ≥ 130 mm Hg, respectively. CONCLUSIONS: Higher levels of bilirubin were inversely associated with cardiometabolic risk factors including adiposity, dyslipidemia, and hypertension. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01484-x. BioMed Central 2022-04-18 /pmc/articles/PMC9017025/ /pubmed/35436955 http://dx.doi.org/10.1186/s12933-022-01484-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Seyed Khoei, Nazlisadat
Wagner, Karl-Heinz
Sedlmeier, Anja M.
Gunter, Marc J.
Murphy, Neil
Freisling, Heinz
Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank
title Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank
title_full Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank
title_fullStr Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank
title_full_unstemmed Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank
title_short Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank
title_sort bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the uk biobank
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017025/
https://www.ncbi.nlm.nih.gov/pubmed/35436955
http://dx.doi.org/10.1186/s12933-022-01484-x
work_keys_str_mv AT seyedkhoeinazlisadat bilirubinasanindicatorofcardiometabolichealthacrosssectionalanalysisintheukbiobank
AT wagnerkarlheinz bilirubinasanindicatorofcardiometabolichealthacrosssectionalanalysisintheukbiobank
AT sedlmeieranjam bilirubinasanindicatorofcardiometabolichealthacrosssectionalanalysisintheukbiobank
AT guntermarcj bilirubinasanindicatorofcardiometabolichealthacrosssectionalanalysisintheukbiobank
AT murphyneil bilirubinasanindicatorofcardiometabolichealthacrosssectionalanalysisintheukbiobank
AT freislingheinz bilirubinasanindicatorofcardiometabolichealthacrosssectionalanalysisintheukbiobank